90 related articles for article (PubMed ID: 26166362)
1. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
[TBL] [Abstract][Full Text] [Related]
2. Expression and anticancer activity analysis of recombinant human uPA1‑43-melittin.
Su M; Chang W; Cui M; Lin Y; Wu S; Xu T
Int J Oncol; 2015 Feb; 46(2):619-26. PubMed ID: 25394558
[TBL] [Abstract][Full Text] [Related]
3. A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitro.
Zhao LP; Xu TM; Kan MJ; Xiao YC; Cui MH
Int J Mol Med; 2016 May; 37(5):1310-6. PubMed ID: 27035617
[TBL] [Abstract][Full Text] [Related]
4. A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Kobayashi H; Suzuki M; Kanayama N; Terao T
Clin Exp Metastasis; 2004; 21(2):159-66. PubMed ID: 15168733
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro.
Takei Y; Mizukami H; Saga Y; Kobayashi H; Suzuki M; Matsushita T; Ozawa K; Suzuki M
Int J Cancer; 2005 Jan; 113(1):54-8. PubMed ID: 15386422
[TBL] [Abstract][Full Text] [Related]
6. Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
Su M; Chang W; Zhang K; Cui M; Wu S; Xu T
Oncol Rep; 2016 Feb; 35(2):1179-85. PubMed ID: 26718643
[TBL] [Abstract][Full Text] [Related]
7. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
[TBL] [Abstract][Full Text] [Related]
9. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
10. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Chambers SK; Wang Y; Gertz RE; Kacinski BM
Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368
[TBL] [Abstract][Full Text] [Related]
11. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
12. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S
Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
14. [Effect of semaphorin4D gene silencing on malignant behavior of human ovarian cancer SKOV3 cells].
Chen Y; Zhang L; Wu HJ; Liu WX; Hao Q
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):324-30. PubMed ID: 21875458
[TBL] [Abstract][Full Text] [Related]
15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
16. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
[TBL] [Abstract][Full Text] [Related]
17. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.
Cai S; Zhang P; Dong S; Li L; Cai J; Xu M
Cell Physiol Biochem; 2018; 45(3):1061-1071. PubMed ID: 29439245
[TBL] [Abstract][Full Text] [Related]
19. Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
Li T; Jiang S
Pharm Biol; 2010 Feb; 48(2):161-5. PubMed ID: 20645833
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
